CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
优化胶质母细胞瘤的 CAR-T 治疗
英文原题：Optimizing CAR-T Therapy for Glioblastoma.
查看英文原题
Optimizing CAR-T Therapy for Glioblastoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞疗法已改变血液系统恶性肿瘤的治疗，但在实体瘤中尚未显示稳定疗效。胶质母细胞瘤是成人最常见的原发性恶性脑肿瘤，临床上仍存在重大未满足需求。将CAR-T 疗法用于胶质母细胞瘤虽初现疗效潜力，但也面临诸多挑战。本文重点综述为提高CAR-T 治疗胶质母细胞瘤疗效而开发的当前及未来策略，包括发现和鉴定新靶抗原、通过新型CAR构建体逆转T细胞功能障碍、采用可调控平台和基因敲除策略，以及利用联合治疗克服对免疫不利的肿瘤微环境。
展开英文摘要原文
Chimeric antigen receptor T-cell therapies have transformed the management of hematologic malignancies but have not yet demonstrated consistent efficacy in solid tumors. Glioblastoma is the most common primary malignant brain tumor in adults and remains a major unmet medical need. Attempts at harnessing the potential of chimeric antigen receptor T-cell therapy for glioblastoma have resulted in glimpses of promise but have been met with substantial challenges.
In this focused review, we discuss current and future strategies being developed to optimize chimeric antigen receptor T cells for efficacy in patients with glioblastoma, including the identification and characterization of new target antigens, reversal of T-cell dysfunction with novel chimeric antigen receptor constructs, regulatable platforms, and gene knockout strategies, and the use of combination therapies to overcome the immune-hostile microenvironment.
论文信息
- 作者
- Tang OY、Binder ZA、O'Rourke DM、Bagley SJ
- 第一作者单位
- Warren Alpert Medical School, Brown University, Providence, RI, 02903, USA.United States
- 通讯作者单位
- Department of Medicine, Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA. sbagley@pennmedicine.upenn.edu.United States
- 文献类型
- 综述
- 期刊
- Molecular diagnosis & therapy2023 Nov
- 原文标识
- PubMed 37700186 · DOI 10.1007/s40291-023-00671-0